Cardax Inc. (CDXI)
| Market Cap | 1.22M |
| Revenue (ttm) | 615,280 |
| Net Income (ttm) | -5.50M |
| Shares Out | 755,847 |
| EPS (ttm) | -7.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.62 |
| Previous Close | $1.62 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.62 |
| Day's Range | 1.62 - 1.62 |
| Day's Volume | 0 |
| 52-Week Range | 1.15 - 19 |
News
There are no news available yet.
About CDXI
Cardax, a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate; and CDX-301, a zeaxanthin pharmaceutical candidate for pharma... [Read more...]
| Industry Biotechnology | |
| CEO David G. Watumull | Employees 11 |
| Stock Exchange OTCMKTS | Ticker Symbol CDXI |
Financial Performance
In 2019, Cardax's revenue was $710,949, a decrease of -52.94% compared to the previous year's $1.51 million. Losses were -$5.09 million, 26.6% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for Cardax is 1.00, which is a decrease of -38.27% from the latest price.